Defence Therapeutics has recently announced the successful testing of a new formulation of its ACCUM-002TM Dimer CDCA-SV40, widely known as AccuTOX®, showcasing its potential as an effective anticancer treatment specifically targeting lung tumours.
The latest results from Defence Therapeutics‘ research expand the horizon of application for AccuTOX® in the treatment of solid cancer tumours. This breakthrough innovation holds promise in transforming the landscape of cancer therapeutics.
Enhanced therapeutic properties against lung tumours
AccuTOX®, an optimisation of the Accum® molecule and platform technology developed by Defence Therapeutics, exhibited remarkable therapeutic properties in recent studies.
It demonstrated efficacy in combatting over a dozen different murine and human cancer cell lines, showcasing its broad potential in cancer treatment.
Initially delivered intranasally with profound impact on blocking tumour growth in mice, Defence Therapeutics encountered a challenge in translating this delivery approach to clinical settings due to the nasal droplet method’s complexity.
To overcome this obstacle, the company employed a nebulising device known as the ‘Anesthesia Mask Nebulizer Delivery System’, manufactured by Kent Scientific Corporation.
Promising tolerability and efficacy
Following meticulous preclinical studies to fine-tune delivery parameters, a maximum tolerated study indicated that rodents tolerated the drug at a dose of 3 mg/kg.
When administered as a monotherapy, AccuTOX® showcased its ability to inhibit the growth of lung nodules, signifying its potential as a standalone treatment against this form of cancer.
These effects were amplified when combined with the immune-checkpoint inhibitor anti-PD1, shown in Figure 1 below.
Sébastien Plouffe, President & CEO of Defence Therapeutics, commented: “We are very excited with the potency of our lead compound, AccuTOX®.
“These studies are important as they show how versatile the application of this drug can be against various indications, and they demonstrate in addition how different formulations or delivery devices can be used to target different tumour types/sites.”
Defence Therapeutics’ groundbreaking advancements in AccuTOX® mark a significant leap forward in the pursuit of effective and targeted cancer treatments, especially in addressing lung tumours.
The successful testing and promising results underscore the potential of this innovative therapy in revolutionising cancer care paradigms.
